PMS Registry
Company Name
Bayer Taiwan Co., Ltd
Protocol Number
21460
Title of Study
Systemic treatment patterns of hepatocellular carcinoma (HCC) in Taiwan
Primary Objective
The primary objective is to describe systemic treatment patterns of unresectable HCC patients in Taiwan whose first-line systemic treatment is sorafenib.
Number of Sites
1
Period of Study
From: to:
Number of Patients
415人
IRB Approval Date
2020/08/15
Publication Plan / Date
2022/12/31